Antiinflammatory therapy with canakinumab for atherosclerotic disease
Version 2 2024-06-04, 15:33Version 2 2024-06-04, 15:33
Version 1 2023-10-24, 23:54Version 1 2023-10-24, 23:54
journal contribution
posted on 2024-06-04, 15:33authored byPM Ridker, BM Everett, T Thuren, JG MacFadyen, WH Chang, C Ballantyne, F Fonseca, J Nicolau, W Koenig, SD Anker, JJP Kastelein, JH Cornel, P Pais, D Pella, J Genest, R Cifkova, A Lorenzatti, T Forster, Z Kobalava, L Vida-Simiti, M Flather, H Shimokawa, H Ogawa, M Dellborg, PRF Rossi, RPT Troquay, P Libby, RJ Glynn, H Krum, J Varigos, P Siostrzonek, P Sinnaeve, N Gotcheva, H Yong, M Urina-Triana, D Milicic, R Vettus, AJ Manolis, F Wyss, A Sigurdsson, A Fucili, I Veze, B Petrauskiene, L Salvador, TO Klemsdal, F Medina, A Budaj, P Otasevic, M Lainscak, KB Seung, P Commerford, M Donath, JJ Hwang, H Kultursay, S Bilazarian, C East, L Forgosh, B Harris, M Ligueros, E Bohula, B Charmarthi, S Cheng, S Chou, J Danik, G McMahon, B Maron, M Ning, B Olenchock, R Pande, T Perlstein, A Pradhan, N Rost, A Singhal, V Taqueti, N Wei, H Burris, A Cioffi, AM Dalseg, N Ghosh, J Gralow, T Mayer, H Rugo, V Fowler, AP Limaye, S Cosgrove, D Levine, R Lopes, J Scott, R Hilkert, G Tamesby, C Mickel, B Manning, J Woelcke, M Tan, S Manfreda, T Ponce, J Kam, R Saini, K Banker, T Salko
Antiinflammatory therapy with canakinumab for atherosclerotic disease